This is a non-material clinical update, no revenue, approval, or partnership data. No trading catalyst until actual data readout.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 5 $1.02entry
- T+1 · 7mo ago 0.00%α −1.38% · $1.02
- T+5 · 6mo ago 0.00%α −1.98% · $1.02
- T+20 · 6mo ago 0.00%α −4.95% · $1.02
- T+60 · 4mo ago +164.71%α +161.97% · $2.70
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Alpha Tau announced that an abstract on its Alpha DaRT combination therapy with pembrolizumab for elderly head and neck cancer patients was accepted for a podium presentation at the AHNS International Conference in July 2026. The filing is a routine clinical milestone update with no new financial data or regulatory approval, and the stock has historically not reacted positively to similar announcements.
Key Facts
- Abstract on Alpha DaRT + pembrolizumab in elderly HNSCC patients accepted for podium presentation at AHNS 12th International Conference (July 18-22, 2026, Boston).
- Presentation scheduled for July 21, 2026, during Proffered Papers session on Radiation and Adjuvant Therapies.
- Study conducted at Hadassah Medical Center, Jerusalem; complete top-line data to be presented.
- No financial figures, revenue, EPS, or guidance changes reported in the filing.
- Prior 20-F (filed March 9, 2026) noted 88,009,737 ordinary shares outstanding as of Dec 31, 2025.
Financial Impact
No financial impact disclosed; pre-revenue clinical-stage company.
Risk Factors
- No regulatory approval or commercial revenue; company remains pre-revenue with significant cash burn.
- Podium presentation acceptance does not guarantee positive clinical data or eventual regulatory approval.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-051929 |
| Document: ea0289093-6k_alphatau.htm | 0001213900-26-051929 |
| Document: 0001213900-26-051929-index-headers.html | 0001213900-26-051929 |
| Document: 0001213900-26-051929-index.html | 0001213900-26-051929 |
| Document: 0001213900-26-051929.txt | 0001213900-26-051929 |
Track record
14 reports on DRTSW
9 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +292.16% at T+60 after the Jun 3, 2026 report. 9 of 9 went positive at some point.
Filters
- Jun 3, 202623w ago 6-K Bullish 7/10 Entry $1.02 to $4.00 ▲ +292.16% +289.66% vs SPY
- Jun 1, 202624w ago 6-K Bullish 7/10 Entry $1.02 to $3.89 ▲ +281.37% +280.14% vs SPY
- May 18, 202626w ago 6-K Neutral 5/10 Entry $1.02 to $3.89 ▲ +281.37% +275.08% vs SPY
- May 11, 202627w ago 6-K Bullish 7/10 Entry $1.02 to $3.37 ▲ +230.39% +226.00% vs SPY
- May 11, 202627w ago 6-K Bullish 6/10 Entry $1.02 to $3.37 ▲ +230.39% +226.00% vs SPY
- May 8, 202627w ago 6-K Neutral 3/10 Entry $1.02 to $3.30 ▲ +223.53% +218.69% vs SPY
- May 8, 202627w ago 6-K Bullish 6/10 Entry $1.02 to $3.30 ▲ +223.53% +218.69% vs SPY
- May 7, 202627w ago 6-K Neutral 3/10 Entry $1.02 to $2.58 ▲ +152.94% +149.11% vs SPY
- May 5, 202627w ago 6-K Neutral 3/10 Viewing Entry $1.02 to $2.70 ▲ +164.71% +161.97% vs SPY
- May 4, 202628w ago 6-K Bullish 7/10 Entry $1.02 to $2.29 ▲ +124.51% +122.65% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers